Robert Lynn, MD
Nephrology · Bronx, NYNPI 1851388862
Payments from drug & device makers
Across 424 payments — averaging $4782.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1M
- Boehringer Ingelheim International GmbH$272K
- GSK$245K
- Vertex$153K
- Astrazeneca UK Limited$134K
- CSL Behring$64K
- plus $153K from 29 others
Across 3 payments — averaging $1781.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$5K
- Eli Lilly$275
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $1,006,913 |
| Boehringer Ingelheim International GmbH | 21 | $271,809 |
| GSK | 74 | $245,402 |
| Vertex | 5 | $153,154 |
| Astrazeneca UK Limited | 3 | $133,696 |
| CSL Behring | 44 | $63,695 |
| Boehringer Ingelheim | 7 | $50,715 |
| Dynavax Technologies Corporation | 34 | $43,694 |
| Eli Lilly | 3 | $24,079 |
| Baxter Healthcare | 15 | $14,267 |
| Ardelyx, Inc. | 8 | $6,293 |
| Amgen(2 entities) | 42 | $5,902 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 7 | $4,111 |
| Vifor Pharma, Inc. | 26 | $2,186 |
| Akebia Therapeutics Inc | 20 | $428 |
| Travere Therapeutics, Inc. | 8 | $185 |
| Fresenius USA Marketing, Inc. | 7 | $164 |
| Vantive US Healthcare LLC | 1 | $145 |
| Calliditas Therapeutics US Inc. | 4 | $118 |
| Aurinia Pharma U.S., Inc. | 5 | $117 |
| Bard Peripheral Vascular, Inc. | 1 | $103 |
| Bayer | 4 | $84 |
| Lilly USA, LLC | 3 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $67 |
| Novo Nordisk | 3 | $60 |
| Novartis | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Pfizer | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Shield Therapeutics Inc | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Merck | 1 | $17 |
| Dexcom, Inc. | 1 | $13 |
How this compares
$2,027,752 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Bronx
- Bruce SpinowitzBronx$837K
- Matthew AbramowitzBronx$749K
- Enver AkalinBronx$312K
- Chang XuBronx$257K
- Joel NeugartenBronx$256K
- Chaim CharytanBronx$204K
- Gill FreiBronx$188K
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.